{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:04:54Z","timestamp":1784534694832,"version":"3.55.0"},"reference-count":17,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Ministry of Health and Welfare"},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Endourology"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>While the da Vinci surgical system has dominated robot-assisted partial nephrectomy (RAPN), its high cost limits accessibility. The Revo-i surgical robot offers a cost-effective alternative with approximately 42% lower cost, but clinical experience in partial nephrectomy (PN) remains limited. This study provides the first clinical comparison of perioperative outcomes between Revo-i and da Vinci Xi systems for RAPN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 124 patients who underwent RAPN between September 2023 and October 2025 at a single tertiary center. Patients were informed about both platforms, and the final system was selected through shared decision-making. Revo-i was preferentially used in patients with cost concerns and low- to intermediate-complexity tumors. Patients were treated using da Vinci Xi (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 79) or Revo-i (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 45) systems. Tumor complexity was stratified by R.E.N.A.L. nephrometry score into low (&lt;7), intermediate (7\u201310), and high (&gt;10) groups. The primary outcome was trifecta achievement (negative surgical margins, warm ischemia time [WIT] &lt;25 minutes, and no complications).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Baseline characteristics were comparable, although the Revo-i group had a lower R.E.N.A.L. score (7\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      8,\n                      <jats:italic toggle=\"yes\">p =<\/jats:italic>\n                      0.004) and fewer hilar tumors (11.1%\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      35.4%,\n                      <jats:italic toggle=\"yes\">p =<\/jats:italic>\n                      0.003). Operative time, blood loss, and hospital stay were similar. No perioperative complications occurred. Overall trifecta achievement was 66.7% for Revo-i and 57.0% for da Vinci (\n                      <jats:italic toggle=\"yes\">p =<\/jats:italic>\n                      0.342). The percentage change in estimated glomerular filtration rate was similar between groups (\u22120.50%\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      \u22120.49%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.410), with no significant differences across tumor complexity subgroups. In low-complexity cases, Revo-i showed shorter WIT (8\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      17 minutes,\n                      <jats:italic toggle=\"yes\">p =<\/jats:italic>\n                      0.003) because of a higher rate of zero-ischemia cases (45.0%\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      9.5%,\n                      <jats:italic toggle=\"yes\">p =<\/jats:italic>\n                      0.015). In high-complexity cases, Revo-i showed longer WIT (50\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      33 minutes,\n                      <jats:italic toggle=\"yes\">p =<\/jats:italic>\n                      0.005) and no trifecta cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Revo-i demonstrates comparable outcomes with da Vinci Xi for low- and intermediate-complexity PN. However, caution is warranted for high-complexity cases because of prolonged WIT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08927790261450707","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:45:07Z","timestamp":1779273907000},"page":"881-887","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Revo-i\n                    <i>vs<\/i>\n                    Da Vinci in Robotic Partial Nephrectomy: First Human Comparison"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4184-8468","authenticated-orcid":false,"given":"Ji Eun","family":"Heo","sequence":"first","affiliation":[{"name":"Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ho","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sik","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woong Kyu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Deuk","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongsoo","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.09.042"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.05.035"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.12.028"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/end.2016.0351"},{"key":"e_1_3_2_6_2","unstructured":"Intuitive. Robotic-assisted surgery with da Vinci systems [Oct 28 2025. Available from: https:\/\/www.intuitive.com\/en-us\/patients\/da-vinci-robotic-surgery"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/rcs.2023"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/end.2021.0421"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.11.024"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2025.02.003"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14245"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.04.020"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2023.0140"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.09.047"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.03.006"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.05.110"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/end.2019.0506"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1683482"}],"container-title":["Journal of Endourology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08927790261450707","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08927790261450707","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08927790261450707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:27:54Z","timestamp":1784532474000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08927790261450707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"alternative-id":["10.1177\/08927790261450707"],"URL":"https:\/\/doi.org\/10.1177\/08927790261450707","relation":{},"ISSN":["0892-7790","1557-900X"],"issn-type":[{"value":"0892-7790","type":"print"},{"value":"1557-900X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]}}}